Tyrosine kinase inhibitors have long served as a foundation for precision oncology, particularly in the treatment of advanced lung cancer. The US Food and Drug Administration has approved twenty-eight such drugs for nine distinct molecular subtypes of the disease. While these therapies have driven significant remissions, sometimes lasting for several years, many patients eventually experience disease recurrence due to acquired resistance.
This resistance typically arises when the target kinase develops mutations in the amino-acid residues surrounding its active site, preventing the inhibitor from binding effectively. According to a study published in Nature, researchers led by Conery et al. have identified an alternative strategy: using targeted protein degraders to eliminate the kinase entirely rather than merely blocking its function.
The approach marks a potential shift in how clinicians address drug-resistant cancers, moving beyond the limitations of traditional inhibition models.
Fascinating, but how do they handle off-target degradation effects? Safety profiles with degraders are notoriously trickier than inhibitors.
Twenty-eight approved drugs still leave so many patients with no options. Hope these degraders move faster to clinical trials.
This is huge. Blocking the enzyme isn’t enough if it mutates; destroying the whole protein seems like the logical next step.